Basics Geron Corporation Geron Corp is a biopharmaceutical company. It supports the clinical stage development of a telomerase inhibitor, imetelstat. IPO Date: July 31, 1996 Sector: Healthcare Industry: Biotech Market Cap: $836.25M Activated in VL: True Average Daily Range Avg Daily Range: $0.11 | 2.89% Avg Daily Range (30 D): $0.03 | 2.59% Avg Daily Range (90 D): $0.03 | 2.66% Institutional Daily Volume Avg Daily Volume: 2.84M Avg Daily Volume (30 D): 6.82M Avg Daily Volume (90 D): 7.15M Trade Size Avg Trade Size (Sh.): 347 Avg Trade Size (Sh.) (30 D): 456 Avg Trade Size (Sh.) (90 D): 478 Institutional Trades Total Inst.Trades: 2,765 Avg Inst. Trade: $1.84M Avg Inst. Trade (30 D): $1.09M Avg Inst. Trade (90 D): $1.15M Avg Inst. Trade Volume: .62M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.26M Avg Closing Trade (30 D): $.88M Avg Closing Trade (90 D): $1.01M Avg Closing Volume: 810.32K     News Dec 4, 2025 @ 5:20 PM Blood Cancer Therapeutics Reach Critical Commercia... Source: Prnewswire Oct 23, 2025 @ 10:14 PM GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & S... Source: Bragar Eagel & Squire, P.C. Oct 22, 2025 @ 12:00 PM Cassava Sciences Appoints Dawn C. Bir to the Board... Source: Cassava Sciences, Inc. Oct 13, 2025 @ 8:34 PM Geron Corporation Announces Executive Leadership T... Source: Geron Corporation Aug 19, 2025 @ 12:00 PM SpyGlass Pharma Appoints Elizabeth O’Farrel... Source: Patrick Mooney Financials   TTM Q3 2025 Q2 2025 Basic EPS $-.12 $-.03 $-.02 Diluted EPS $-.12 $-.03 $-.02 Revenue $ 183.4M $ 47.23M $ 49.04M Gross Profit $ $ $ Net Income / Loss $ -79.99M $ -18.43M $ -16.38M Operating Income / Loss $ -63.1M $ -13.89M $ -12.45M Cost of Revenue $ $ $ Net Cash Flow $ 17.81M $ .39M $ -6.01M PE Ratio